Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
LVTX Stock Overview
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments.
LAVA Therapeutics Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$2.51 |
52 Week High | US$8.38 |
52 Week Low | US$2.28 |
Beta | 0 |
1 Month Change | -5.64% |
3 Month Change | -29.89% |
1 Year Change | -56.27% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -82.45% |
Recent News & Updates
Shareholder Returns
LVTX | US Biotechs | US Market | |
---|---|---|---|
7D | -5.4% | 1.4% | 3.6% |
1Y | -56.3% | -19.6% | -9.6% |
Return vs Industry: LVTX underperformed the US Biotechs industry which returned -21.7% over the past year.
Return vs Market: LVTX underperformed the US Market which returned -10.2% over the past year.
Price Volatility
LVTX volatility | |
---|---|
LVTX Average Weekly Movement | 12.2% |
Biotechs Industry Average Movement | 12.6% |
Market Average Movement | 7.7% |
10% most volatile stocks in US Market | 16.9% |
10% least volatile stocks in US Market | 3.2% |
Stable Share Price: LVTX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: LVTX's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2016 | 57 | Steve Hurly | https://www.lavatherapeutics.com |
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-051, which is in Phase 1/2a clinical trial for blood cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia; and LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer.
LAVA Therapeutics Fundamentals Summary
LVTX fundamental statistics | |
---|---|
Market Cap | US$64.70m |
Earnings (TTM) | -US$36.16m |
Revenue (TTM) | US$5.00m |
12.9x
P/S Ratio-1.8x
P/E RatioIs LVTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
LVTX income statement (TTM) | |
---|---|
Revenue | US$5.00m |
Cost of Revenue | US$26.08m |
Gross Profit | -US$21.08m |
Other Expenses | US$15.08m |
Earnings | -US$36.16m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | -1.40 |
Gross Margin | -421.64% |
Net Profit Margin | -723.20% |
Debt/Equity Ratio | 4.2% |
How did LVTX perform over the long term?
See historical performance and comparisonValuation
Is LVTX undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Analyst Forecast
Key Valuation Metric
Which metric is best to use when looking at relative valuation for LVTX?
Other financial metrics that can be useful for relative valuation.
What is LVTX's n/a Ratio? | |
---|---|
n/a Ratio | 0x |
n/a | n/a |
Market Cap | US$64.70m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | n/a |
Enterprise Value/EBITDA | n/a |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does LVTX's PS Ratio compare to its peers?
LVTX PS Ratio vs Peers |
---|
Company | PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 19.8x | ||
ATHX Athersys | 6.4x | -38.4% | US$70.3m |
HARP Harpoon Therapeutics | 3.1x | 36.6% | US$70.8m |
SLS SELLAS Life Sciences Group | 66.6x | 79.6% | US$66.6m |
ICCC ImmuCell | 3.1x | n/a | US$63.1m |
LVTX LAVA Therapeutics | 12.9x | -34.4% | US$64.7m |
Price-To-Sales vs Peers: LVTX is good value based on its Price-To-Sales Ratio (12.9x) compared to the peer average (19.8x).
Price to Earnings Ratio vs Industry
How does LVTX's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Sales vs Industry: LVTX is good value based on its Price-To-Sales Ratio (12.9x) compared to the US Biotechs industry average (17.2x)
Price to Sales Ratio vs Fair Ratio
What is LVTX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 12.9x |
Fair PS Ratio | 0.005x |
Price-To-Sales vs Fair Ratio: LVTX is expensive based on its Price-To-Sales Ratio (12.9x) compared to the estimated Fair Price-To-Sales Ratio (0x).
Share Price vs Fair Value
What is the Fair Price of LVTX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate LVTX's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate LVTX's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
Future Growth
How is LAVA Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Future Growth Score
0/6Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
-7.4%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: LVTX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: LVTX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: LVTX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: LVTX's revenue is expected to decline over the next 3 years (-34.4% per year).
High Growth Revenue: LVTX's revenue is forecast to decline over the next 3 years (-34.4% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if LVTX's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Past Performance
How has LAVA Therapeutics performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
-16.9%
Last years earnings growth
Earnings and Revenue History
Quality Earnings: LVTX is currently unprofitable.
Growing Profit Margin: LVTX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if LVTX's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare LVTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LVTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (24.5%).
Return on Equity
High ROE: LVTX has a negative Return on Equity (-33.36%), as it is currently unprofitable.
Discover strong past performing companies
Financial Health
How is LAVA Therapeutics's financial position?
Financial Health Score
5/6Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: LVTX's short term assets ($126.7M) exceed its short term liabilities ($16.3M).
Long Term Liabilities: LVTX's short term assets ($126.7M) exceed its long term liabilities ($4.8M).
Debt to Equity History and Analysis
Debt Level: LVTX has more cash than its total debt.
Reducing Debt: Insufficient data to determine if LVTX's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: LVTX has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: LVTX has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 57.1% each year.
Discover healthy companies
Dividend
What is LAVA Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate LVTX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate LVTX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if LVTX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if LVTX's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as LVTX has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
2.9yrs
Average management tenure
CEO
Steve Hurly (54 yo)
3.17yrs
Tenure
Mr. Stephen Allen Hurly, also known as Steve, MSc, MBA, serves as Chief Executive Officer, President and Executive Director at Lava Therapeutics N.V. since June 2019. Mr. Hurly was Chief Executive Officer...
Leadership Team
Experienced Management: LVTX's management team is considered experienced (2.9 years average tenure).
Board Members
Experienced Board: LVTX's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
LAVA Therapeutics N.V.'s employee growth, exchange listings and data sources
Key Information
- Name: LAVA Therapeutics N.V.
- Ticker: LVTX
- Exchange: NasdaqGS
- Founded: 2016
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$64.699m
- Shares outstanding: 25.78m
- Website: https://www.lavatherapeutics.com
Number of Employees
Location
- LAVA Therapeutics N.V.
- Yalelaan 60
- Utrecht
- Utrecht
- 3584 CM
- Netherlands
Listings
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2022/08/15 00:00 |
End of Day Share Price | 2022/08/15 00:00 |
Earnings | 2022/03/31 |
Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.